A new study reveals a twice-yearly injectable HIV prevention drug, Lenacapavir, offers 100% protection for pregnant and breastfeeding women. The findings stem from a sub-study of the larger Phase 3 PURPOSE 1 clinical trial assessing the drug's safety and effectiveness. Lenacapavir is used as pre-exposure prophylaxis (PrEP), preventing HIV infection in high-risk individuals. This breakthrough offers a crucial advancement in HIV prevention, particularly for vulnerable populations. The results indicate a significant improvement over daily oral PrEP options, potentially increasing adherence and overall protection. This injectable option could dramatically reduce mother-to-child transmission rates and improve health outcomes. Further details of the study have been published recently.